Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 02:04PM ET
9.36
Dollar change
-0.43
Percentage change
-4.34
%
IndexRUT P/E- EPS (ttm)-2.47 Insider Own3.40% Shs Outstand48.97M Perf Week-11.82%
Market Cap461.32M Forward P/E- EPS next Y-1.11 Insider Trans-4.90% Shs Float47.58M Perf Month-25.97%
Income-120.91M PEG- EPS next Q-0.39 Inst Own104.94% Short Float8.33% Perf Quarter-43.38%
Sales225.03M P/S2.05 EPS this Y36.26% Inst Trans-0.40% Short Ratio7.55 Perf Half Y-41.25%
Book/sh9.01 P/B1.04 EPS next Y21.31% ROA-11.34% Short Interest3.96M Perf Year-56.88%
Cash/sh9.11 P/C1.03 EPS next 5Y- ROE-21.87% 52W Range9.00 - 21.93 Perf YTD-39.54%
Dividend Est.- P/FCF- EPS past 5Y-45.48% ROI-13.72% 52W High-57.30% Beta1.62
Dividend TTM- Quick Ratio10.22 Sales past 5Y78.51% Gross Margin34.28% 52W Low4.06% ATR (14)0.78
Dividend Ex-Date- Current Ratio10.73 EPS Y/Y TTM-220.05% Oper. Margin-31.56% RSI (14)27.07 Volatility7.86% 6.85%
Employees1170 Debt/Eq0.88 Sales Y/Y TTM-9.19% Profit Margin-53.73% Recom2.20 Target Price17.89
Option/ShortYes / Yes LT Debt/Eq0.87 EPS Q/Q-172.16% Payout- Rel Volume0.56 Prev Close9.79
Sales Surprise-7.13% EPS Surprise-24.53% Sales Q/Q-13.09% EarningsMay 07 AMC Avg Volume524.32K Price9.36
SMA20-12.89% SMA50-32.41% SMA200-34.57% Trades Volume210,422 Change-4.34%
Date Action Analyst Rating Change Price Target Change
May-03-24Downgrade B. Riley Securities Buy → Neutral $22 → $19
Apr-04-24Resumed Jefferies Buy $17 → $21
Mar-13-24Reiterated Needham Buy $19 → $18
Aug-17-23Initiated Morgan Stanley Equal-Weight $16
Aug-10-23Downgrade Stephens Overweight → Equal-Weight $15
Jul-18-23Downgrade UBS Buy → Neutral $28 → $17
Jul-17-23Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jul-13-23Downgrade SVB Securities Outperform → Market Perform $30 → $10
Jan-19-22Upgrade ROTH Capital Neutral → Buy $90
Nov-05-21Downgrade ROTH Capital Buy → Neutral $78 → $90
May-17-24 02:33AM
May-08-24 02:54PM
04:03AM
May-07-24 09:56PM
06:18PM
04:08PM Loading…
04:08PM
May-03-24 10:12AM
06:41AM
Apr-30-24 08:30AM
Apr-25-24 10:02AM
Mar-13-24 09:16AM
Mar-12-24 05:52PM
05:30PM
04:05PM
Feb-27-24 08:30AM
10:00AM Loading…
Feb-15-24 10:00AM
Feb-13-24 09:55AM
Nov-27-23 08:30AM
Nov-21-23 03:26PM
Nov-16-23 08:30AM
Nov-09-23 05:23PM
Nov-08-23 06:05PM
04:05PM
Nov-02-23 08:30AM
Oct-26-23 10:02AM
Oct-25-23 08:30AM
Oct-12-23 08:30AM
Oct-10-23 08:30AM
Oct-09-23 04:05PM
Sep-14-23 08:30AM
07:14AM Loading…
Aug-10-23 07:14AM
Aug-09-23 05:30PM
04:05PM
Aug-02-23 08:30AM
Jul-31-23 08:53AM
Jul-23-23 08:17AM
Jul-13-23 12:24PM
11:17AM
Jul-12-23 04:05PM
12:56PM
Jun-29-23 08:39AM
May-25-23 08:02AM
May-12-23 07:15AM
May-04-23 06:05PM
04:05PM
Apr-27-23 10:02AM
08:30AM
Apr-25-23 08:30AM
Apr-01-23 08:54AM
Mar-28-23 08:30AM
Mar-16-23 03:46AM
Mar-13-23 06:00AM
Mar-08-23 01:15PM
Feb-23-23 06:40PM
04:05PM
Feb-15-23 08:30AM
Jan-29-23 07:31AM
Jan-26-23 10:55AM
Jan-18-23 08:30AM
Dec-20-22 08:30AM
Dec-19-22 07:15AM
Nov-08-22 06:56AM
Nov-07-22 08:10PM
05:03AM
Nov-03-22 06:45PM
04:05PM
Oct-27-22 08:30AM
05:32AM
Sep-08-22 08:30AM
Aug-08-22 02:42PM
Aug-06-22 10:18AM
Aug-05-22 09:55AM
Aug-04-22 07:15PM
04:05PM
Jul-28-22 08:30AM
Jul-01-22 08:57AM
May-05-22 07:05PM
04:05PM
Apr-28-22 08:30AM
Apr-20-22 05:59PM
Apr-19-22 12:24PM
Apr-18-22 03:11PM
08:30AM
Mar-30-22 05:00PM
Mar-11-22 03:40PM
Feb-24-22 06:30PM
04:05PM
Feb-23-22 10:00AM
Feb-17-22 03:02PM
Feb-15-22 08:30AM
Feb-09-22 09:29AM
Feb-08-22 09:38AM
Feb-01-22 05:38PM
Jan-31-22 05:35PM
Jan-28-22 05:46AM
Jan-27-22 08:30AM
Jan-26-22 05:38PM
Jan-21-22 05:38PM
09:38AM
Jan-05-22 01:38PM
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BERMAN RICHARD JDirectorMay 15 '24Sale13.418,105108,693100,000May 16 05:30 PM
ZECCHINI EDWARD JChief Digital and Tech OfficerMay 14 '24Sale13.373,44346,04260,051May 15 07:28 PM
SHELTON JERRELLChief Executive OfficerMar 25 '24Sale17.542,63146,154692,182Mar 26 08:09 PM
Sawicki Mark WChief Scientific OfficerMar 25 '24Sale17.541,36723,98077,444Mar 26 08:08 PM
STEFANOVICH ROBERTChief Financial OfficerMar 25 '24Sale17.541,07918,928128,333Mar 26 08:12 PM
SHELTON JERRELLPresident, CEOMar 15 '24Option Exercise4.80100,000480,000749,253Mar 19 07:48 PM
Mandalam RamkumarDirectorMar 15 '24Option Exercise5.408,33445,00446,404Mar 19 07:49 PM
BADDOUR LINDADirectorMar 15 '24Option Exercise0.001,111021,690Mar 19 07:48 PM
SHELTON JERRELLPresident, CEOMar 15 '24Sale15.3057,039872,884634,352Mar 19 07:48 PM
Mandalam RamkumarDirectorMar 15 '24Sale14.683,21747,22643,187Mar 19 07:49 PM
Sawicki Mark WChief Scientific OfficerMar 15 '24Sale15.431,31220,24773,061Mar 19 07:50 PM
STEFANOVICH ROBERTChief Financial OfficerMar 15 '24Sale15.431,03515,972123,662Mar 19 07:51 PM
SHELTON JERRELLPresident, CEOMar 11 '24Sale16.353,72360,880636,951Mar 19 07:48 PM
Sawicki Mark WChief Scientific OfficerMar 11 '24Sale16.351,41823,18874,373Mar 19 07:50 PM
STEFANOVICH ROBERTChief Financial OfficerMar 11 '24Sale16.351,11918,298124,697Mar 19 07:51 PM
STEFANOVICH ROBERTChief Financial OfficerMar 09 '24Option Exercise0.002,6660125,816Mar 19 07:51 PM
SHELTON JERRELLPresident, CEOMar 09 '24Option Exercise0.008,2500640,674Mar 19 07:48 PM
Sawicki Mark WChief Scientific OfficerMar 09 '24Option Exercise0.002,666075,791Mar 19 07:50 PM
Hariri Robert JDirectorDec 14 '23Sale16.8980013,51212,716Dec 18 07:19 PM
Hariri Robert JDirectorDec 11 '23Sale15.501,00015,50013,516Dec 13 06:02 PM
Sawicki Mark WChief Scientific OfficerSep 12 '23Option Exercise12.791,00012,79073,125Sep 13 05:01 PM
Hariri Robert JDirectorSep 06 '23Sale13.601,50020,40014,516Sep 12 06:01 PM
SHELTON JERRELLSee RemarksSep 01 '23Option Exercise1.8754,000100,980659,299Sep 05 05:53 PM
SHELTON JERRELLSee RemarksSep 01 '23Sale14.2726,875383,407632,424Sep 05 05:53 PM
STEFANOVICH ROBERTChief Financial OfficerAug 29 '23Option Exercise3.0716,00049,120123,150Aug 30 05:30 PM
Last Close
Jun 18 02:03PM ET
3.01
Dollar change
-0.11
Percentage change
-3.53
%
Index- P/E- EPS (ttm)-5.50 Insider Own51.53% Shs Outstand21.78M Perf Week-9.88%
Market Cap65.56M Forward P/E- EPS next Y- Insider Trans190.77% Shs Float10.56M Perf Month0.33%
Income-181.41M PEG- EPS next Q- Inst Own3.83% Short Float6.04% Perf Quarter-42.34%
Sales14.79M P/S4.43 EPS this Y- Inst Trans369.24% Short Ratio16.45 Perf Half Y60.88%
Book/sh1.56 P/B1.93 EPS next Y- ROA-61.05% Short Interest0.64M Perf Year-62.84%
Cash/sh0.01 P/C242.81 EPS next 5Y- ROE-186.56% 52W Range1.59 - 8.24 Perf YTD21.67%
Dividend Est.- P/FCF- EPS past 5Y- ROI-322.10% 52W High-63.48% Beta0.44
Dividend TTM- Quick Ratio0.14 Sales past 5Y- Gross Margin-42.83% 52W Low89.31% ATR (14)0.29
Dividend Ex-Date- Current Ratio0.19 EPS Y/Y TTM-628.37% Oper. Margin-658.47% RSI (14)41.02 Volatility4.93% 9.02%
Employees- Debt/Eq2.02 Sales Y/Y TTM-20.93% Profit Margin-1226.72% Recom1.00 Target Price25.00
Option/ShortYes / Yes LT Debt/Eq0.86 EPS Q/Q-15726.96% Payout- Rel Volume0.85 Prev Close3.12
Sales Surprise-42.97% EPS Surprise-70.83% Sales Q/Q-8.44% Earnings- Avg Volume38.75K Price3.01
SMA20-6.63% SMA50-10.75% SMA200-6.02% Trades Volume23,576 Change-3.53%
Date Action Analyst Rating Change Price Target Change
Jan-30-23Downgrade Morgan Stanley Equal-Weight → Underweight $5 → $1
Dec-22-22Downgrade Oppenheimer Outperform → Perform
Jun-22-22Initiated H.C. Wainwright Buy $15
Apr-06-22Downgrade Truist Buy → Hold $10
Jan-28-22Initiated Oppenheimer Outperform $9
Nov-24-21Initiated Morgan Stanley Equal-Weight $9
Jun-03-24 08:38AM
May-24-24 05:15PM
May-14-24 09:15AM
Apr-22-24 08:00AM
Apr-19-24 05:30PM
04:30PM Loading…
Apr-18-24 04:30PM
Apr-15-24 08:00AM
Apr-08-24 09:00AM
Mar-26-24 09:00AM
Mar-20-24 09:15AM
Mar-14-24 09:15AM
Mar-12-24 09:20AM
Mar-07-24 09:35AM
Feb-23-24 04:10PM
Feb-14-24 04:05PM
09:00AM Loading…
Feb-01-24 09:00AM
Jan-25-24 09:00AM
Jan-18-24 01:40PM
Jan-04-24 01:00PM
Jan-03-24 07:30PM
12:00PM
Nov-24-23 01:15PM
Oct-18-23 09:00AM
Sep-07-23 04:10PM
Aug-29-23 09:00AM
Jul-27-23 09:07AM
09:00AM
Jul-18-23 09:00AM
Jun-29-23 04:05PM
Jun-01-23 09:15AM
10:56AM Loading…
May-23-23 10:56AM
May-19-23 04:21PM
May-10-23 09:00AM
May-01-23 04:01PM
Apr-27-23 09:00AM
Apr-12-23 09:00AM
Apr-05-23 09:00AM
Apr-04-23 09:00AM
Apr-03-23 09:00AM
Mar-28-23 10:55AM
09:00AM
Feb-02-23 07:53AM
Feb-01-23 04:05PM
Jan-26-23 04:17PM
Jan-11-23 01:35PM
01:22PM
Jan-06-23 08:10AM
Jan-04-23 04:10PM
Dec-05-22 08:00AM
Nov-30-22 09:55AM
Nov-10-22 05:00PM
04:10PM
09:10AM
Oct-06-22 08:00AM
Oct-03-22 08:00AM
Sep-27-22 08:00AM
Sep-26-22 08:00AM
Sep-15-22 02:29PM
Sep-06-22 04:10PM
Aug-09-22 04:10PM
Jul-27-22 08:00AM
Jul-04-22 10:08AM
Jun-08-22 04:10PM
Jun-03-22 08:00AM
May-18-22 08:30AM
May-16-22 04:10PM
Mar-31-22 04:05PM
Mar-15-22 04:05PM
12:59PM
Feb-15-22 04:05PM
Jan-27-22 05:38PM
05:38PM
Jan-18-22 08:00AM
Dec-27-21 08:00AM
Dec-15-21 09:04AM
Dec-13-21 08:00AM
Nov-29-21 08:00AM
Nov-16-21 05:35AM
Nov-15-21 08:00AM
Nov-12-21 04:05PM
Sep-20-21 08:00AM
08:00AM
Aug-16-21 05:15PM
Aug-04-21 07:00PM
Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lim Kok Thay10% OwnerJan 12 '24Buy0.2521,410,9835,331,33551,473,762Jan 17 05:22 PM
Hariri Robert JChief Executive OfficerOct 05 '23Buy0.169,357,5851,484,11328,570,434Oct 10 09:48 PM
Hariri Robert JChief Executive OfficerSep 29 '23Buy0.179,064,5391,500,18119,212,849Oct 10 09:48 PM